Welcome to our dedicated page for Outset Medical news (Ticker: OM), a resource for investors and traders seeking the latest updates and insights on Outset Medical stock.
Outset Medical, Inc. (symbol: OM) is a pioneering medical technology company committed to revolutionizing the dialysis experience. The company’s primary product, Tablo, is an innovative dialysis machine designed to simplify and streamline the process of Renal Replacement Therapy. By focusing on a patient-centric approach, Outset Medical places patient care, ease of use, and cost-efficiency at the forefront of its operations.
The Tablo dialysis system is built with a user-friendly touchscreen display that offers step-by-step visual and conversational instructions, making it accessible to both patients and caregivers, regardless of their experience level. This intuitive design dramatically reduces the complexity and cost associated with traditional dialysis treatments. Tablo can be used across various settings, including hospitals, chronic care dialysis clinics, and at home, making it a versatile solution for renal care.
Outset Medical’s mission is to improve the care experience for patients, families, providers, and physicians, while also enhancing cost-efficiencies for healthcare providers. The company achieves this by combining expertise from different healthcare fields, fostering an environment of cross-disciplinary innovation. This approach has led to significant advancements in dialysis technology and patient care.
Recent achievements include regulatory approvals and partnerships aimed at expanding Tablo’s reach and improving its functionalities. Financially, Outset Medical has shown robust growth, supported by a dedicated team of professionals and continuous innovation in their product offerings. The company's efforts are geared towards giving people their time back by reducing the dialysis process's complexity and duration.
Stay updated with the latest developments and news about Outset Medical, Inc. to learn how this industry leader is transforming renal care.
Outset Medical, Inc. (NASDAQ: OM) announced its expected fourth quarter and fiscal year 2022 revenues, projecting approximately
Outset Medical, Inc. (Nasdaq: OM) announces its participation in the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023, at 11:15 am PT / 2:15 pm ET. The company focuses on innovative dialysis technology, specifically the Tablo Hemodialysis System, designed to reduce costs and complexity in dialysis treatments. The Tablo system, FDA cleared for both hospital and home use, allows healthcare providers to deliver dialysis care more efficiently. A live and archived webcast will be available on Outset's Investors webpage.
Outset Medical, Inc. (Nasdaq: OM) announces participation in a virtual panel at the BofA Securities Home Care Conference on December 6, 2022, at 12:10 PM PT. The discussion will feature CEO Leslie Trigg and CMO Michael Aragon, alongside two home dialysis patients, focusing on home hemodialysis and end-stage renal disease management. A live and archived webcast will be accessible on the Investors section of Outset’s website. Outset's Tablo® Hemodialysis System aims to simplify dialysis and enhance patient care.
Outset Medical, Inc. announced a remarkable 5,000% revenue growth, totaling
Outset Medical, Inc. (Nasdaq: OM) announced management participation in two investor conferences. The Stifel 2022 Healthcare Conference is set for November 15, 2022, at 5:35am PT. The Jefferies London Healthcare Conference follows on November 17, 2022, at 5:55am PT. Both sessions will be accessible via live and archived webcasts on the Outset website. Outset is known for its innovative Tablo Hemodialysis System, which simplifies dialysis cost and complexity, enhancing patient care from hospitals to home.
Outset Medical reported a 10.8% revenue growth in Q3 2022, reaching $27.8 million, compared to $25.1 million in Q2 2022. Gross margin improved to 15.6% from 11.2% in Q3 2021. Full-year revenue guidance is now set between $111 million and $113 million, up from previous guidance of $105 million to $110 million. Key achievements include resuming shipments to home patients and a five-year contract with the Department of Veterans Affairs.
Outset Medical, Inc. (Nasdaq: OM) has secured $300 million in senior secured credit facilities from SLR Capital Partners, including a $250 million term loan and a $50 million revolving credit facility. The term loan includes a $200 million commitment, extendable to $250 million, with interest-only payments for up to 54 months. Outset has drawn $100 million at closing. The financing aims to enhance the company's balance sheet and support its dialysis technology advancements. Maturity is set for November 1, 2027.
Outset Medical announces eight new abstracts highlighting home dialysis innovations at the American Society of Nephrology's Kidney Week 2022. Research indicates that patients using the Tablo Hemodialysis System experience lower attrition rates compared to other modalities, demonstrating high treatment adherence with 100% patient retention. Key findings emphasize that both patients and clinicians can effectively use the technology. Abstracts also showcase improved efficiency, cost reduction, and successful home dialysis program implementation, reflecting Outset's commitment to enhancing kidney care.
Outset Medical, Inc. (OM) will release its third-quarter financial results on November 8, 2022, after market close. A conference call is scheduled for 2:00 PM PT on the same day, featuring CEO Leslie Trigg and CFO Nabeel Ahmed. Interested parties can register online to receive dial-in information. Outset is known for its innovative Tablo® Hemodialysis System, designed to make dialysis more accessible and efficient, supporting care from hospital to home. This technology integrates water purification and dialysate production, enhancing patient experience and operational efficiency.
Outset Medical, Inc. (Nasdaq: OM) announced participation in a fireside chat at the 20th Annual Morgan Stanley Global Healthcare Conference on September 13, 2022, at 11:55am PT / 2:55pm ET. The event will be accessible through a live and archived webcast on the company’s website. Outset Medical is known for its innovative Tablo Hemodialysis System, designed to simplify dialysis for providers and enhance patient experiences. This technology enables dialysis delivery in various settings with integrated water purification and data analytics capabilities.
FAQ
What is the current stock price of Outset Medical (OM)?
What is the market cap of Outset Medical (OM)?
What is Outset Medical, Inc.?
What product does Outset Medical offer?
How does the Tablo dialysis system work?
In what settings can Tablo be used?
What is the company's main mission?
Who can use the Tablo machine?
What is unique about the Tablo machine?
How does Outset Medical foster innovation?
What recent achievements does Outset Medical have?
How has Outset Medical performed financially?
